Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering
Adaptive Biotechnologies priced an upsized $300 million offering of 0% convertible senior notes due 2031, increasing from a previously announced $250 million. Net proceeds are expected to total approximately $290.8 million, with the company planning to use funds to repay the OrbiMed Purchase Agreement and support MRD business initiatives.
Key figures
- Deal Value Usd
- 300000000
- Repurchase Amount
- 25000000
- Option amount
- 45000000
- Capped call cost
- 22300000
- Conversion price
- 24.11
- Principal amount
- 300000000
- Net proceeds base
- 290800000
- Conversion premium
- 40.0%
- Capped call premium
- 100%
- Jwca purchase amount
- 10000000
- Capped call cap price
- 34.44
- Net proceeds full exercise
- 334500000
- Shares repurchased concurrently
- 1451800
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.